血管生成在人类非霍奇金淋巴瘤中的作用。
The role of angiogenesis in human non-Hodgkin lymphomas.
机构信息
Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Section of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy.
出版信息
Neoplasia. 2013 Mar;15(3):231-8. doi: 10.1593/neo.121962.
Abstract
The role of angiogenesis in the growth of lymphomas and survival of patients with leukemias and other hematological malignancies has become evident since 1994. Angiogenic factors, such as vascular endothelial growth factor and its receptors together with other tumor microenvironment components, including myelo-monocytic cell, mast cells, endothelial progenitor cells, and circulating endothelial cells, have been shown to be important in the progression and maintenance of lymphoproliferative disorders. In this review article, we present an overview of the literature focusing on the relationship between angiogenesis and disease progression and the recent advantages in the antiangiogenic treatment in human non-Hodgkin lymphomas.
摘要
自 1994 年以来，血管生成在淋巴瘤的生长以及白血病和其他血液系统恶性肿瘤患者的生存中的作用已经变得很明显。血管生成因子，如血管内皮生长因子及其受体，以及其他肿瘤微环境成分，包括髓系单核细胞、肥大细胞、内皮祖细胞和循环内皮细胞，已被证明在淋巴增生性疾病的进展和维持中很重要。在这篇综述文章中，我们概述了文献，重点关注血管生成与疾病进展之间的关系，以及在人类非霍奇金淋巴瘤的抗血管生成治疗方面的最新进展。
相似文献
1
The role of angiogenesis in human non-Hodgkin lymphomas.血管生成在人类非霍奇金淋巴瘤中的作用。
Neoplasia. 2013 Mar;15(3):231-8. doi: 10.1593/neo.121962.
2
Insights in Hodgkin Lymphoma angiogenesis.霍奇金淋巴瘤血管生成研究进展。
Leuk Res. 2014 Aug;38(8):857-61. doi: 10.1016/j.leukres.2014.05.023. Epub 2014 Jun 4.
3
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy.B 细胞非霍奇金淋巴瘤：血管生成及其抗血管生成治疗的重要性。
Angiogenesis. 2020 Nov;23(4):515-529. doi: 10.1007/s10456-020-09729-7. Epub 2020 May 25.
4
Mast cells contribute to the angiogenesis in non-Hodgkin lymphoma. An immunohistochemical study based on the relationship with microvessel density.肥大细胞促进非霍奇金淋巴瘤中的血管生成。一项基于与微血管密度关系的免疫组织化学研究。
Rom J Morphol Embryol. 2011;52(3 Suppl):1091-6.
5
Antiangiogenic therapies in non-Hodgkin's lymphoma.抗血管生成疗法在非霍奇金淋巴瘤中的应用。
Curr Cancer Drug Targets. 2011 Nov;11(9):1030-43. doi: 10.2174/156800911798073014.
6
Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma.非霍奇金淋巴瘤中的血管生成与肥大细胞：血管免疫母细胞性T细胞淋巴瘤中的强相关性
Leuk Lymphoma. 2001 Aug;42(4):709-20. doi: 10.3109/10428190109099333.
7
Endothelial progenitor cells in non-Hodgkin's lymphoma.非霍奇金淋巴瘤中的内皮祖细胞
Haematologica. 2007 Apr;92(4):433-4. doi: 10.3324/haematol.11367.
8
Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients.淋巴瘤患者循环及活检来源的内皮祖细胞的特征及临床相关性
Haematologica. 2007 Apr;92(4):469-77. doi: 10.3324/haematol.10723.
9
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.非霍奇金淋巴瘤中的血管生成与抗血管生成治疗
Ann Oncol. 2009 Mar;20(3):413-24. doi: 10.1093/annonc/mdn666. Epub 2008 Dec 16.
10
Angiogenesis in lymphoproliferative disorders: a therapeutic target?淋巴增生性疾病中的血管生成：一个治疗靶点？
Curr Opin Hematol. 2005 Jul;12(4):279-83. doi: 10.1097/01.moh.0000168521.76120.7b.
引用本文的文献
1
Immune profiling of canine B cell lymphoma reveals cross-species conservation of prognostic markers.犬B细胞淋巴瘤的免疫谱分析揭示了预后标志物的跨物种保守性。
Sci Rep. 2025 Aug 4;15(1):28385. doi: 10.1038/s41598-025-13389-2.
2
Identification of superficial invasive and indolent lymphomatous lymph nodes by multiple ultrasonographic vascular imaging.通过多种超声血管成像鉴别浅表浸润性和惰性淋巴瘤性淋巴结
Sci Rep. 2025 Mar 22;15(1):9886. doi: 10.1038/s41598-025-93545-w.
3
Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.芯片上的淋巴瘤模型表明，淋巴结基质细胞可促进弥漫性大B细胞淋巴瘤的存活和迁移。
Mater Today Bio. 2025 Feb 7;31:101544. doi: 10.1016/j.mtbio.2025.101544. eCollection 2025 Apr.
4
Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line.没食子酸增强奥拉帕尼诱导的细胞死亡并减轻人骨肉瘤U2OS细胞系对奥拉帕尼的耐药性。
Curr Issues Mol Biol. 2025 Feb 7;47(2):104. doi: 10.3390/cimb47020104.
5
In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico.在体、体外和计算机模拟抗癌症活性的羊驼叶：一种在墨西哥可食用和药用的植物。
Molecules. 2024 Apr 24;29(9):1956. doi: 10.3390/molecules29091956.
6
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.节拍化疗与药物重新利用：肿瘤学中的范式转变。
Heliyon. 2024 Jan 14;10(3):e24670. doi: 10.1016/j.heliyon.2024.e24670. eCollection 2024 Feb 15.
7
Non-invasive detection of lymphoma with circulating tumor DNA features and protein tumor markers.利用循环肿瘤DNA特征和蛋白质肿瘤标志物对淋巴瘤进行无创检测。
Front Oncol. 2024 Jan 19;14:1341997. doi: 10.3389/fonc.2024.1341997. eCollection 2024.
8
A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.一种新型血管生成相关评分模型可预测弥漫性大B细胞淋巴瘤的预后风险和治疗反应性。
Clin Exp Med. 2023 Nov;23(7):3781-3797. doi: 10.1007/s10238-023-01127-9. Epub 2023 Jul 4.
9
A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images.基于超声图像预测弥漫性大 B 细胞淋巴瘤预后的模型。
Sci Rep. 2023 Feb 27;13(1):3346. doi: 10.1038/s41598-023-30533-y.
10
Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.Chiauranib的临床前研究表明，它通过VEGFR2/ERK/STAT3信号通路抑制转化型滤泡性淋巴瘤。
Pharmaceuticals (Basel). 2022 Dec 22;16(1):15. doi: 10.3390/ph16010015.
本文引用的文献
1
Specific tumor-stroma interactions of EBV-positive Burkitt's lymphoma cells in the chick chorioallantoic membrane.EBV 阳性伯基特淋巴瘤细胞在鸡胚绒毛尿囊膜中的特定肿瘤-基质相互作用
Vasc Cell. 2012 Mar 9;4(1):3. doi: 10.1186/2045-824X-4-3.
2
Intussusceptive microvascular growth in tumors.肿瘤内陷性微血管生长。
Cancer Lett. 2012 Mar 28;316(2):126-31. doi: 10.1016/j.canlet.2011.10.040. Epub 2011 Nov 4.
3
Aquaporin-4 expression in primary human central nervous system lymphomas correlates with tumour cell proliferation and phenotypic heterogeneity of the vessel wall.水通道蛋白-4 在原发性人中枢神经系统淋巴瘤中的表达与肿瘤细胞增殖和血管壁的表型异质性相关。
Eur J Cancer. 2012 Mar;48(5):772-81. doi: 10.1016/j.ejca.2011.10.022. Epub 2011 Nov 17.
4
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.硼替佐米联合 R-CVP 方案治疗未经治疗的晚期滤泡性淋巴瘤安全有效：加拿大国家癌症研究所临床试验组的 II 期研究。
J Clin Oncol. 2011 Sep 1;29(25):3396-401. doi: 10.1200/JCO.2010.33.6594. Epub 2011 Aug 1.
5
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.来那度胺单药治疗不同组织起源复发/难治性转化型非霍奇金淋巴瘤的差异效应。
Br J Haematol. 2011 Aug;154(4):477-81. doi: 10.1111/j.1365-2141.2011.08781.x. Epub 2011 Jun 28.
6
Mast cells, angiogenesis, and tumour growth.肥大细胞、血管生成与肿瘤生长。
Biochim Biophys Acta. 2012 Jan;1822(1):2-8. doi: 10.1016/j.bbadis.2010.11.010. Epub 2010 Dec 2.
7
Genomic profiles in B cell lymphoma.B 细胞淋巴瘤的基因组图谱。
Int J Hematol. 2010 Sep;92(2):238-45. doi: 10.1007/s12185-010-0662-1. Epub 2010 Aug 27.
8
Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.淋巴瘤内皮细胞优先表达 Tim-3，并通过介导免疫逃逸促进淋巴瘤的进展。
J Exp Med. 2010 Mar 15;207(3):505-20. doi: 10.1084/jem.20090397. Epub 2010 Feb 22.
9
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.与其他组织学亚型相比，接受硼替佐米治疗的滤泡性淋巴瘤患者的治疗反应时间更长。
Clin Cancer Res. 2010 Jan 15;16(2):719-26. doi: 10.1158/1078-0432.CCR-08-2647. Epub 2010 Jan 12.
10
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.来那度胺单药治疗可使复发或难治性惰性非霍奇金淋巴瘤产生持久缓解。
J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5.
Zotero 插件